However, E.G7-OVA cells expressing SULT2B1b (E.G7-OVA-SULT) exhibited resistance to this therapy, with a lower percentage of tumor-infiltrating OTI CD8+ T cells (Fig. 4A and Supplementary Figure 2A). The gene discussed is CD8A; the disease is neoplasm.